Delivery Order SPE2DB25D7055-SPE2DB25FXYNR
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Linzess 290 micrograms capsules (30-count units) valued at $3,746.36 on September 29, 2025, with completion targeted for September 30, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $1,014.90 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 6, 2025, for the supply of Linzess 145 micrograms capsules (30-count units). This non-set-aside contract represents a child delivery order under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $1,909.80 to AmerisourceBergen Drug Corp for Linzess 72 microgram capsules (30-count units) on September 3, 2025, with an ultimate completion date of September 4, 2025. This competitive award, which carries no set-aside designation, represents a firm fixed-price delivery order for pharmaceutical supply to support federal medical procurement needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in...
- The Defense Logistics Agency awarded a delivery order valued at $6,017.50 to AmerisourceBergen Drug Corp for the supply of Linzess 145 mcg capsules (30-count units), with an ultimate completion date of September 11, 2025. This competitive, firm fixed-price delivery order was issued on September 10, 2025, with performance directed to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's broader Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,247.40 to AmerisourceBergen Drug Corp for Linzess 145 microgram capsules (30-count units) under a firm fixed-price contract. The award was made on September 16, 2025, with an ultimate completion date of September 17, 2025. This non-set-aside contract represents a competitive award to the prime contractor, with the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Linzess 72 microgram capsules (30-count unit of use packaging) with a ceiling value of $1,155.69. This firm fixed-price delivery order, which is expected to be completed by August 15, 2025, represents a non-competitive set-aside award and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $1,064.49 to AmerisourceBergen Drug Corp for Linzess 290 microgram capsules (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions...
- The Defense Logistics Agency awarded a $11,335.78 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Linzess 290 microgram capsules in quantities of 30 units. This firm fixed-price contract represents a competitively awarded, non-set-aside procurement with a completion date of August 19, 2025. The product will be performed and delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Linzess 72 mg capsules in a 30-count unit pack, with a contract ceiling value of $1,495.59 and an ultimate completion date of July 21, 2025. This firm fixed price delivery order represents a non-competitive award and is classified as a child contract under AmerisourceBergen's larger federal contracting framework. The performance location is the company's corporate office in...
- The Defense Logistics Agency awarded a delivery order valued at $7,330.67 to AmerisourceBergen Drug Corp for Linzess 290 microgram capsules (30-count units) on September 16, 2025, with completion expected by September 17, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and is executed against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support...
- SPE2DB25D7055Indefinite Delivery Contract
- SPE2DB25D7055-SPE2DB25FXYNRDelivery Order
The Defense Logistics Agency awarded a $3,706.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Linzess 72 microgram capsules (30-count units) on May 27, 2025, with completion expected by May 28, 2025. This is a non-set-aside, competitively awarded contract with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion vehicle running through December 2026 that serves as a comprehensive global pharmaceutical support platform for military healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, regularly fulfills federal medical procurement needs through its extensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. Linzess is a gastrointestinal medication used to treat chronic idiopathic constipation and irritable bowel syndrome, addressing medical needs within the Defense Health Agency and broader military healthcare system. The firm fixed-price structure and small transaction value are typical of routine supply orders executed under DLA's pharmaceutical prime vendor framework, which leverages multiple contractors to ensure reliable drug availability across global military operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.7k | 5/27/25 |